Investors |

News

22 October 2018

LexaGene successfully unveils LX2™ beta prototype design on October 20th, 2018 to an enthusiastic gathering of veterinary professionals at the American Association of Veterinary Laboratory Diagnosticians (AAVLD) conference.

Read More

09 October 2018

LexaGene to unveil LX2™ Beta Prototype design for the veterinary market at an upcoming industry event.

Read More

04 September 2018

LexaGene announces that company President, Daryl Rebeck, will present at two upcoming investor conferences that are taking place in September 2018

Read More

26 July 2018

LexaGene announces that the company has begun beta development of its flagship pathogen detection system.

Read More

11 July 2018

LexaGene completes C$5.75 Million Bought Deal Financing. Underwriters Exercise Over-Allotment Option in Full.

Read More

19 June 2018

LexaGene announces C$5.0 Million bought deal with a syndicate of underwriters led by Canaccord Genuity Corp.

Read More

18 June 2018

LexaGene names medical device veteran Joseph Caruso to Board of Directors. Mr. Caruso was responsible for the successful worldwide commercial launch of dozens of medical devices over his 30-year career.

Read More

06 June 2018

LexaGene announces a collaboration with Texas A&M Veterinary Medical Diagnostics Laboratory to begin testing canine dog urine samples on LexaGene’s LX6 prototype.

Read More

29 May 2018

LexaGene has entered into an agreement with the Stanford University School of Medicine to incorporate cancer sequencing technology into a new product. This collaboration involves using targeted sequencing technology developed in the laboratory of Dr. Hanlee Ji, a Stanford associate professor of medicine, in combination with LexaGene’s microfluidic instrument.

Read More

15 May 2018

LexaGene announces that its prototype for more effective pathogen detection is now generating data, and is capable of identifying E. coli and Staph.

Read More

04 April 2018

LexaGene has entered into a collaboration with Ethos Veterinary Health to begin testing canine dog urine samples on LexaGene’s LX6 prototype.

Read More

01 March 2018

LexaGene appoints Jeffrey Mitchell as Chief Financial Officer of the Company. Mr. Mitchell has over two decades of financial and SEC experience

Read More